Zkusit zdarma
MaxCyte, Inc.

MaxCyte, Inc.

MXCT
Cena:
$ 1.04
-0.02 (-1.89%)
Valuace
70
Růst
0
Zdraví
60
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

2:01 13-05-2026

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript...

MaxCyte Q1 Earnings Call Highlights

MaxCyte Q1 Earnings Call Highlights

21:09 12-05-2026

MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as managemen...

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

18:40 12-05-2026

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Es...

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

16:05 12-05-2026

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 mi...

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

16:05 29-04-2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-en...

MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts

MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Price Target from Analysts

3:46 24-04-2026

MaxCyte, Inc. (NASDAQ: MXCT - Get Free Report) has been assigned a consensus rating of "Hold" from t...

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16:05 31-03-2026

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi...

MaxCyte Q4 Earnings Call Highlights

MaxCyte Q4 Earnings Call Highlights

3:07 26-03-2026

MaxCyte (NASDAQ: MXCT) executives told investors the company made "meaningful progress" in 2025 desp...

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

2:14 25-03-2026

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript...

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates

18:37 24-03-2026

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Es...

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

16:05 24-03-2026

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary an...

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

8:05 23-03-2026

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engi...

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

8:05 24-02-2026

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng...

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

16:05 23-02-2026

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng...

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

8:05 12-01-2026

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leadi...

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

9:00 01-12-2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac...

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

19:11 12-11-2025

MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Mahe...

MaxCyte Announces Planned CFO Transition in 2026

MaxCyte Announces Planned CFO Transition in 2026

16:08 12-11-2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-en...

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

16:05 12-11-2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-eng...

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

8:05 05-11-2025

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at t...

close

MAXCYTE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

12-01-2026
ROCKVILLE, MD., JAN. 12, 2026 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

CELLARES APPOINTS FORMER MAXCYTE COMMERCIAL CHIEF ALI SOLEYMANNEZHAD AS CHIEF COMMERCIAL OFFICER TO LEAD GLOBAL IDMO EXPANSION, CATALYZE NEXT WAVE OF PARTNERSHIPS, PREPARE FOR IPO

01-12-2025
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--CELLARES, THE FIRST INTEGRATED DEVELOPMENT AND MANUFAC...
Více zde

MAXCYTE ANNOUNCES PLANNED CFO TRANSITION IN 2026

12-11-2025
ROCKVILLE, MD., NOV. 12, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT), A LEADING, CELL-EN...
Více zde

MAXCYTE REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND REITERATES FULL YEAR 2025 REVENUE GUIDANCE

12-11-2025
ROCKVILLE, MD., NOV. 12, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT), A LEADING, CELL-ENG...
Více zde

MAXCYTE REPORTS PRELIMINARY THIRD QUARTER 2025 FINANCIAL RESULTS AND REITERATES FULL YEAR 2025 REVENUE GUIDANCE

05-11-2025
MAXCYTE WILL NOW HOST ITS EARNINGS CONFERENCE CALL ON NOVEMBER 12, 2025 MANAGEMENT WILL PRESENT AT T...
Více zde

MAXCYTE TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 5, 2025

08-10-2025
ROCKVILLE, MD., OCT. 08, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT), A LEADING, CELL-ENG...
Více zde

MAXCYTE ANNOUNCES STRATEGIC PLATFORM LICENSE AGREEMENT WITH MOONLIGHT BIO TO ADVANCE T CELL THERAPIES FOR SOLID TUMORS

06-10-2025
MAXCYTE'S FLOW ELECTROPORATION® TECHNOLOGY WILL SUPPORT EFFICIENT GENE DELIVERY TO ADVANCE MOONLIGH...
Více zde

MAXCYTE ANNOUNCES OPERATIONAL RESTRUCTURING TO REDUCE COSTS AND ACCELERATE PATH TO PROFITABILITY

22-09-2025
ROCKVILLE, MD., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT), A LEADING, CELL-E...
Více zde

MAXCYTE SIGNS PLATFORM LICENSE AGREEMENT WITH ADICET BIO

04-08-2025
MAXCYTE'S FLOW ELECTROPORATION® TECHNOLOGY AND EXPERT™ PLATFORM TO SUPPORT DEVELOPMENT OF ADICET'...
Více zde

MAXCYTE ANNOUNCES STRATEGIC PLATFORM LICENSING AGREEMENT WITH ANOCCA AB TO ADVANCE TCR-T CELL THERAPY PIPELINE

31-07-2025
MAXCYTE'S FLOW ELECTROPORATION® TECHNOLOGY WILL SUPPORT NON-VIRAL GENE EDITING IN THE MANUFACTURE O...
Více zde

MAXCYTE TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

09-07-2025
ROCKVILLE, MD., JULY 09, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT), A LEADING, CELL-ENG...
Více zde

PHC ANNOUNCES EXCLUSIVE DISTRIBUTION OF MAXCYTE® EXPERT™ PLATFORM IN JAPAN

01-07-2025
TOKYO--(BUSINESS WIRE)--THE BIOMEDICAL DIVISION OF PHC CORPORATION (HEADQUARTERS: CHIYODA-KU, TOKYO;...
Více zde

MAXCYTE AND ORI BIOTECH COLLABORATE TO IMPROVE MANUFACTURING EFFICIENCIES AND BROADEN ADOPTION OF AUTOLOGOUS CELLULAR THERAPIES

11-06-2025
MAXCYTE AND ORI BIOTECH SUCCESSFULLY INTEGRATE THEIR EXPERT™ AND IRO® PLATFORMS TO IMPROVE THE YI...
Více zde

MAXCYTE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND REITERATES FULL YEAR 2025 GUIDANCE

07-05-2025
ROCKVILLE, MD, MAY 7, 2025 — MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADING, CELL-ENGINEERIN...
Více zde

MAXCYTE TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 7, 2025

10-04-2025
ROCKVILLE, MD., APRIL 10, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

MAXCYTE REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2025 GUIDANCE

11-03-2025
ROCKVILLE, MD., MARCH 11, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

MAXCYTE SIGNS STRATEGIC PLATFORM LICENSE WITH TG THERAPEUTICS TO ADVANCE ITS AUTOIMMUNE CELL THERAPEUTICS PROGRAMS

12-02-2025
ROCKVILLE, MD., FEB. 12, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MARCH 11, 2025, AND PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

07-02-2025
ROCKVILLE, MD., FEB. 07, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

GLANCY PRONGAY & MURRAY LLP ANNOUNCES INVESTIGATION OF MAXCYTE, INC. (MXCT)

30-01-2025
NEW YORK--(BUSINESS WIRE)--GLANCY PRONGAY & MURRAY LLP (“GPM”) ANNOUNCES ITS INVESTIGATION OF MA...
Více zde

MAXCYTE® ACQUIRES SEQURE DX TO BROADEN CELL ENGINEERING OFFERINGS WITH ON-TARGET AND OFF-TARGET EDITING ASSESSMENTS

30-01-2025
ROCKVILLE, MD., JAN. 30, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

13-01-2025
ROCKVILLE, MD., JAN. 13, 2025 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

MAXCYTE ANNOUNCES RETIREMENT OF BOARD MEMBER ART MANDELL

23-12-2024
ROCKVILLE, MD., DEC. 22, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

MAXCYTE ANNOUNCES STREAMLINED OPERATIONS AND RAISES 2024 REVENUE GUIDANCE

09-12-2024
ROCKVILLE, MD., DEC. 08, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC. , (NASDAQ: MXCT; LSE: MXCT), A LEADI...
Více zde

MAXCYTE CELEBRATES 25 YEARS OF INNOVATION DRIVING CELL ENGINEERING-BASED THERAPEUTICS

13-11-2024
SINCE 1999, MAXCYTE'S NON-VIRAL CELL ENGINEERING INNOVATIONS HAVE HELPED LAUNCH PIONEERING CELL AND ...
Více zde

MAXCYTE REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND UPDATES FULL YEAR 2024 GUIDANCE

06-11-2024
ROCKVILLE, MD., NOV. 06, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC. (NASDAQ: MXCT; LSE: MXCT), A LEADING...
Více zde

MAXCYTE TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

31-10-2024
ROCKVILLE, MD., OCT. 31, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE APPOINTS CYNTHIA COLLINS TO ITS BOARD OF DIRECTORS

15-10-2024
ROCKVILLE, MD., OCT. 15, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON NOVEMBER 6, 2024

11-10-2024
ROCKVILLE, MD., OCT. 11, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE APPOINTS ALI SOLEYMANNEZHAD AS CHIEF COMMERCIAL OFFICER

10-10-2024
ROCKVILLE, MD., OCT. 10, 2024 (GLOBE NEWSWIRE) -- MAXCYTE, INC., (NASDAQ: MXCT; LSE: MXCT), A LEADIN...
Více zde

MAXCYTE SIGNS STRATEGIC PLATFORM LICENSE WITH KAMAU THERAPEUTICS TO ACCELERATE THE DEVELOPMENT OF CELL THERAPIES FOR GENETIC DISEASES

16-09-2024
KAMAU TO USE MAXCYTE'S FLOW ELECTROPORATION® TECHNOLOGY AND EXPERT™ PLATFORM TO SUPPORT ITS HOMOL...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-11-13 00:00:0010-QStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-09-22 01:00:008-KStáhnout
2025-09-22 00:00:008-KStáhnout
2025-08-11 01:00:008-KStáhnout
2025-08-11 00:00:008-KStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-25 01:00:008-KStáhnout
2025-06-25 00:00:008-KStáhnout
2025-06-18 01:00:008-KStáhnout
2025-06-18 00:00:008-KStáhnout
2025-05-08 01:00:0010-QStáhnout
2025-05-08 00:00:0010-QStáhnout
2025-05-07 01:00:008-KStáhnout
2025-05-07 00:00:008-KStáhnout
2025-03-11 00:00:008-KStáhnout
2025-03-11 00:00:0010-KStáhnout
2025-03-10 23:00:008-KStáhnout
2025-03-10 23:00:0010-KStáhnout
2025-01-30 00:00:008-KStáhnout
2025-01-29 23:00:008-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-12-27 00:00:008-KStáhnout
2024-12-26 23:00:008-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-11-06 00:00:008-KStáhnout
2024-11-06 00:00:0010-QStáhnout
2024-11-05 23:00:008-KStáhnout
2024-11-05 23:00:0010-QStáhnout
2024-10-15 01:00:008-KStáhnout
2024-10-15 00:00:008-KStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-06-12 01:00:008-KStáhnout
2024-06-12 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-03-12 00:00:008-KStáhnout
2024-03-12 00:00:0010-KStáhnout
2024-03-11 23:00:008-KStáhnout
2024-03-11 23:00:0010-KStáhnout
2024-03-05 00:00:008-KStáhnout
2024-03-04 23:00:008-KStáhnout
2024-01-26 00:00:008-KStáhnout
2024-01-25 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-12-11 00:00:008-KStáhnout
2023-12-10 23:00:008-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-10-04 01:00:008-KStáhnout
2023-10-04 00:00:008-KStáhnout
2023-08-09 01:00:008-KStáhnout
2023-08-09 01:00:0010-QStáhnout
2023-08-09 00:00:008-KStáhnout
2023-08-09 00:00:0010-QStáhnout
2023-06-23 01:00:008-KStáhnout
2023-06-23 00:00:008-KStáhnout
2023-05-10 01:00:008-KStáhnout
2023-05-10 01:00:0010-QStáhnout
2023-05-10 00:00:008-KStáhnout
2023-05-10 00:00:0010-QStáhnout
2023-03-28 01:00:008-KStáhnout
2023-03-28 00:00:008-KStáhnout
2023-03-15 00:00:008-KStáhnout
2023-03-15 00:00:0010-KStáhnout
2023-03-14 23:00:008-KStáhnout
2023-03-14 23:00:0010-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-05 23:00:008-KStáhnout
2022-12-01 00:00:008-KStáhnout
2022-11-30 23:00:008-KStáhnout
2022-11-09 00:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:008-KStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-08-10 01:00:008-KStáhnout
2022-08-10 01:00:0010-QStáhnout
2022-08-10 00:00:008-KStáhnout
2022-08-10 00:00:0010-QStáhnout
2022-06-30 01:00:008-KStáhnout
2022-06-30 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-04-12 01:00:008-KStáhnout
2022-04-12 00:00:008-KStáhnout
2022-03-22 00:00:008-KStáhnout
2022-03-22 00:00:0010-KStáhnout
2022-03-21 23:00:008-KStáhnout
2022-03-21 23:00:0010-KStáhnout
2022-01-24 00:00:008-KStáhnout
2022-01-23 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-11-02 00:00:008-KStáhnout
2021-11-01 23:00:008-KStáhnout
2021-10-01 01:00:008-KStáhnout
2021-10-01 00:00:008-KStáhnout
2021-09-17 01:00:008-KStáhnout
2021-09-17 00:00:008-KStáhnout
2021-09-13 01:00:0010-QStáhnout
2021-09-13 00:00:0010-QStáhnout
2021-08-04 01:00:008-KStáhnout
2021-08-04 00:00:008-KStáhnout
preloader